R Retreatment in 1st Relapsed DLBCL
- Sponsor
- Shanghai Jiao Tong University School of Medicine
- Study ID
- NCT00980304
- Phase
- PHASE2
- Status
- Unknown
Conditions
- Lymphomas
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 65 Years
- Healthy Volunteers
- Not accepted
Interventions
- Rituximab — DRUG
Study Details
It is a phase II , multicenter, open label clinical trial. Only the relapsed DLBCL patients after 1st line induction treatment of 6\~8 cycles of RCHOP-like chemo will be enrolled to receive 3 cycles of RICE as salvage therapy. After treatment each patient should be followed up for 2 years.
Key Dates
- Status verified
- Sep 2009
Arms
- Experimental: Rituximab in combination with ICE as salvage therapy
Related Studies
- Specimen Collections From Participants With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and CancerRecruiting · National Cancer Institute (NCI) · Bethesda, Maryland
- Collection of Tissue Samples for Cancer ResearchRecruiting · National Cancer Institute (NCI) · Sacramento, California
- A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell LymphomasPHASE1 · Recruiting · M.D. Anderson Cancer Center · Houston, Texas